Abbott’s Freestyle Libre 2 Gains Medicare Coverage
FreeStyle Libre 2 is the only integrated continuous glucose monitoring system that continuously measures the user's blood glucose without fingersticks.
You may also be interested in...
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
The medtech industry advocacy group issued a white paper on best methods for Medicare coverage of telehealth, remote patient monitoring and other digital technology.
The new continuous glucose sensor is the smallest and thinnest in the world, according to Abbott.